公开(公告)号：US09446043B2

公开(公告)日：2016-09-20

申请号：US14647939

申请日：2013-11-26

Applicant: Novartis AG

Inventor： Dale Porter ,  Caroline Emery ,  Lujian Tan ,  Padmaja Yerramilli-Rao

IPC: A61K31/517 ,  A61K31/496 ,  A61K31/4184 ,  A61K31/4025 ,  A61K31/404 ,  A61K45/06 ,  A61K31/506

CPC classification number: A61K31/517 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/496 ,  A61K31/506 ,  A61K45/06 ,  A61K2300/00

Abstract: A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract translation: 一种药物组合，其包含（a）蛋白激酶C（PKC）抑制剂化合物或其药学上可接受的盐，和（b）至少一种丝裂原活化蛋白激酶（MEK）抑制剂或其药学上可接受的盐，以及任选的药学上可接受的盐 载体，用于同时，分开或顺次施用; 这种组合在增殖性疾病治疗中的应用; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。

公开(公告)号：US20200246331A1

公开(公告)日：2020-08-06

申请号：US16535214

申请日：2019-08-08

Applicant: Novartis AG

Inventor： Ensar Halilovic ,  Caroline Emery

IPC: A61K31/496 ,  A61K45/06 ,  A61K31/517 ,  A61K31/497 ,  A61P35/00 ,  A61K31/506

Abstract: The present disclosure relates to a pharmaceutical combination, e.g. a product, comprising a combination of (a) a MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof and a PKC pathway inhibitor of formula III, formula IV, formula V or formula VI or a pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, data carriers and related disclosure embodiments. The disclosure further relates to use of an MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof, alone for use in the treatment of a proliferative disease.

公开(公告)号：US20180243293A1

公开(公告)日：2018-08-30

申请号：US15751954

申请日：2016-08-11

Applicant: Novartis AG

Inventor： Ensar Halilovic ,  Caroline Emery

IPC: A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/497 ,  A61P35/00

CPC classification number: A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/517 ,  A61K45/06 ,  A61P35/00 ,  A61K2300/00

Abstract: The present disclosure relates to a pharmaceutical combination, e.g. a product, comprising a combination of (a) a MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof and a PKC pathway inhibitor of formula III, formula IV, formula V or formula VI or a pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, data carriers and related disclosure embodiments. The disclosure further relates to use of an MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof, alone for use in the treatment of a proliferative disease.